summari ew report underli revenu
underli ahead estim
street adj ep
report came consensu
ahead estim ew underli global tavr
transcathet aortic valv replac sale
easili top consensu expect
ew tavr perform reflect high-teen
sale growth us mid-teen procedur growth ou
expect contribut
transcathet mitral/tricuspid
therapi tmtt modest regard
outlook ew rais top-lin guidanc
expect underli growth come
around top-end rang ew expect
tavr sale includ underli
tavr growth top-end rang bottom-
line ew increas ep guidanc
report pipeline/oper front
hand updat notabl ew expect low-
risk tavr indic fda vs late previous
centera discontinu strateg reason
chang estim rais sale estim
underli adj ep estim
report rais sale estim
report lower adj ep
estim report increas ew
price target base
came street expect
estim underli tavr growth
quarter comfort surpass estim ew
tavr perform reflect high-teen sale growth
us mid-teen procedur growth ou manag attribut
tavr market acceler sever potenti factor impact
low-risk data increas tavr awar public
season borderlin patient receiv tavr minor
increas cap continu access program get
insight ou market dynam report
earn august ew impli tavr guidanc
math underli modest deceler
think larg manag conservat
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
notabl tavr updat call sever notabl tavr pipeline/oper updat
manag expect low-risk approv fda sapien sapien ultra vs late
previous centera ew self-expand tavr valv discontinu strateg
reason note centera recent issu deliver manag
remain pleas perform physician feedback regard latest-gen sapien ultra
ew note expect ultra account major european tavr sale year-end
progress tmtt expect contribut transcathet mitral/tricuspid therapi tmtt
rel modest ew continu focu physician train procedur success
patient outcom launch pascal ou ew said clasp iid degen mitral
regurgit pivot trial continu enrol clasp iif function mitral regurgit
 pivot trial still expect initi late alreadi fda approv begin
transcathet mitral valv replac front manag said continu work evoqu
sapien earli feasibl set remain track start sapien pivot trial
late tricuspid ew continu push pascal cardioband forwardwhil forma
put shelf perman manag expect pascal go pivot trial tricuspid set
later year cardioband tricuspid expect begin pivot studi later date
ew continu expect sale contribut tmtt product
inspiri lead surgic structur heart ew report surgic structur heart ssh sale
underli in-lin consensus/our estim result driven
solid growth ou partial off-set lower surgic aortic heart valv procedur due tavr
adopt manag note inspiri resilia aortic surgic valv continu exhibit growth
region see good traction particularli among activ patient regard harpoon ew said
expect eu commerci launch late vs prior expect mid-year due slower
regulatori environ europ
critic post anoth solid quarter ew report critic cc sale
underli beat consensu miss estim result driven
strong perform across categori led hemospher eu sale ew close acquisit
casm mid-april manag note integr fore-sight technolog
hemospher underway casm contribut ew sale
top bottom-lin outlook rais call ew rais sale guidanc
underli growth guidanc top-end rang ew also
rais tavr sale guidanc expect tavr underli growth
come top-end rang ew maintain underli target
surgic structur heart busi rais outlook critic care underli
growth manag expect critic care sale come around top-end
guidanc rang regard currenc expect impact sale fx continu
headwind move ew reiter guidanc follow
 item gross margin sg spend sale spend sale
tax rate excl special item bottom-lin ew rais ep guidanc
report appear larg reflect ep
beat manag note call expect expens come higher previous
revenu ep guidanc ew guid sale estim impli
underli growth midpoint compar prior consensu
previou estim ew ep guidanc report
street expect previou estim
metricswfconsensuswfconsensusrevenu us aortic heart mitral heart heart valv factset wfconsensusrevenu margin compani report secur llc estim factset visibl alpha explicitli state consensu estim visibl alpha may vari base broker contribut vs actual vs medic technolog
price target
price target assum ep estim risk includ greater
share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
edward lifesci incom statementin million except per share good sold excl gross oper oper expens expens incom pre-tax debt net adj dilut analysi gross bp bp bp oper bp growthnet incom dilut oper share qtr/qtr except dilut compani report secur llc estim edward lifesci corpor
